51. Vasoactive intestinal peptide stimulates turkey prolactin gene expression by increasing transcription rate and enhancing mRNA stability
- Author
-
Seungkwon You, G R Pitts, Douglas N. Foster, Z Tong, and M. E. El Halawani
- Subjects
endocrine system ,medicine.medical_specialty ,Turkeys ,endocrine system diseases ,Transcription, Genetic ,Vasoactive intestinal peptide ,Dot blot ,Endocrinology ,Drug Stability ,Transcription (biology) ,Pituitary Gland, Anterior ,Internal medicine ,medicine ,Animals ,Secretion ,Northern blot ,RNA, Messenger ,RNA Processing, Post-Transcriptional ,Molecular Biology ,Cells, Cultured ,Messenger RNA ,Chemistry ,Molecular biology ,Prolactin ,Kinetics ,Gene Expression Regulation ,Cytoplasm ,Dactinomycin ,Female ,Immunization ,hormones, hormone substitutes, and hormone antagonists ,Vasoactive Intestinal Peptide - Abstract
This study evaluates the transcriptional and post-transcriptional regulation of prolactin (PRL) by vasoactive intestinal peptide (VIP). Pituitary nuclei from laying (control), incubating (with enhanced VIP secretion), and VIP-immunized laying turkey hens, and from pituitary cells cultured with or without VIP were used in nuclear run-on transcription assays. Cytoplasmic PRL mRNA was analyzed by slot blot hybridization. PRL transcription was greater in hyperprolactinemic incubating birds (PRL/beta-actin=3.33) than in laying birds (PRL/beta-actin=1.83). VIP-immunoneutralized birds had 47% and 51% decreases in PRL transcription and cytoplasmic PRL mRNA, respectively when compared with laying birds. In primary pituitary cell cultures, VIP significantly increased the transcription rate of PRL (3.8-fold) and cytoplasmic PRL mRNA (3.2-fold) compared with that of non-VIP-treated pituitary cells. The stability of pre-existing PRL mRNA was measured by Northern blot analysis after addition of actinomycin D. PRL mRNA half-lives were calculated using a two-component model, with a first-long component of 18.0+/-1.0 h and a second-short component of 3.7+/-0.7 h in non-VIP-treated pituitary cells. Both half-lives were significantly increased (53. 2+/-6.9 and 26.3+/-4.3 h) in VIP-treated cells. The present data show that VIP acts to stimulate PRL expression by up-regulating the transcription rate of PRL and by enhancing PRL mRNA stability.
- Published
- 1998